Planning an NIH Application involving Basic Experimental Studies with Humans (BESH)?

February 12, 2026

On January 29, NIH announced that Basic Experimental Studies with Humans (BESH) will no longer be considered clinical trials by the NIH. See NOT-OD-26-032.

What’s changing?

  • Beginning with applications submitted for due dates on or after May 25, 2026, BESH will no longer be considered as clinical trials by NIH.
  • As a result, BESH studies will not be required to follow NIH clinical trial requirements, including registration and results reporting in ClinicalTrials.gov.
  • BESH must continue to follow all other applicable laws and regulations applicable to human subjects protections and the NIH Data Management and Sharing Policy. 

NIH anticipates expiring all BESH-specific NOFOs with due dates on or after May 25, 2026. After that time, BESH research can be accepted through the Clinical Trials Not Allowed companions of these NOFOs.

NIH will issue a forthcoming Guide Notice with detailed guidance on any necessary instruction or system updates to reflect this revised classification.

Resources

Editor's Note: After publication, we added the third bullet above for clarity.

Categories: Top Stories

Related News

FY25 Inclusion Data for NIH-Supported Clinical Research Now Available by NIH Spending Category

In May, we shared NIH-wide fiscal year (FY) 2025 enrollment data on the sex, race, ethnicity, and age of participants in NIH-supported clinical research, offering a broad view of inclusion across the NIH portfolio. More detailed FY25 enrollment data are now available through the NIH Research, Condition, and Disease Categorization (RCDC) Inclusion Statistics Report.

New Resources

What We Heard From You Regarding the Proposed Cap on Simultaneous NIH Research Project Grant Support, and Our Next Steps

In June, we sought your feedback on a proposed approach to cap the number of Research Project Grants (RPG) a researcher can be principal investigator on simultaneously (NOT-OD-26-086). The proposal explored whether limits on simultaneous RPG support could contribute to a more balanced research portfolio. Here, we share some high-level outcomes from your thoughtful and helpful comments, which will inform our next steps.

Top Stories
For technical issues E-mail OER Webmaster